Beta-Interferon, Glatiramer Acetate Cost-Effective in MSBeta-Interferon, Glatiramer Acetate Cost-Effective in MS

A new analysis from the UK has suggested that both beta-interferon and glatiramer acetate delay disability and are cost-effective for the long-term treatment of multiple sclerosis. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news